Literature DB >> 647627

Clinical and immunologic studies of disseminated BCG infection.

S A Rosenberg, C Seipp, H F Sears.   

Abstract

Eight patients with disseminated BCG infection following injection of BCG into primary melanomas have been studied. These patients developed persistent fevers beginning 9 to 20 days following BCG injection. Severe liver function abnormalities occurred in all patients and peaked approximately 20 days following BCG injection. The persistent fevers, and clinical signs and symptoms of disseminated BCG infection lasted from 7 to 22 days before subsiding. Liver function abnormalities sometimes took six months to return to normal. Evidence of granulomas in liver and bone marrow were present. The natural course of this disease did not appear to be affected by therapy with isoniazid (INH). In vitro immunologic studies revealed a severe depression of lymphocyte reactivity in five of six patients sequentially tested. Wide dissemination of BCG from the site of injection is a severe complication of BCG therapy. The clinical course of this disease and suggestions for management are described in this paper.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 647627     DOI: 10.1002/1097-0142(197805)41:5<1771::aid-cncr2820410519>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  A case of BCG sepsis with bone marrow and liver involvement after intravesical BCG instillation.

Authors:  B Dederke; E O Riecken; T Weinke
Journal:  Infection       Date:  1998 Jan-Feb       Impact factor: 3.553

Review 2.  Differential diagnoses of bone marrow granuloma.

Authors:  A Eid; W Carion; J S Nystrom
Journal:  West J Med       Date:  1996-06

3.  Studies of proliferative responses by long-term-cryopreserved peripheral blood mononuclear cells to bacterial components associated with periodontitis.

Authors:  G A Miller; M F Hickey; M M D'Alesandro; B K Nicoll
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

Review 4.  The role of immunotherapy in the management of patients with malignant melanoma.

Authors:  J E Goodnight; D L Morton
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

5.  Immunotherapy of guinea pigs with dermal and visceral tumor implants: comparison of living and nonliving BCG.

Authors:  E Yarkoni; L Peters; H J Rapp; M G Hanna; J T Hunter
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

6.  The immunopathological effects of intracolonic injection of Mycobacterium bovis BCG cell wall emulsions in guinea pigs.

Authors:  G L Cockerell; R W O'Donnell; M M Zgola
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

7.  Immunotherapy of a guinea pig hepatoma with mycobacterial vaccines: comparison of BCG cell walls and cell wall skeletons.

Authors:  E Yarkoni; H J Rapp
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

8.  Complications of intravesical bacillus calmette-guérin.

Authors:  Liam C Macleod; Tin C Ngo; Mark L Gonzalgo
Journal:  Can Urol Assoc J       Date:  2014-07       Impact factor: 1.862

9.  Effect of route of Mycobacterium bovis BCG administration on induction of suppression of sporozoite immunity in rodent malaria.

Authors:  L L Smrkovski
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.